The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis by Kollareddy, Madhu et al.
                          Kollareddy, M., Sherrard, A., Park, J. H., Szemes, M., Gallacher, K., Melegh,
Z., ... Malik, K. (2017). The small molecule inhibitor YK-4-279 disrupts
mitotic progression of neuroblastoma cells, overcomes drug resistance and
synergizes with inhibitors of mitosis. Cancer Letters, 403, 74-85.
https://doi.org/10.1016/j.canlet.2017.05.027
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.canlet.2017.05.027
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://doi.org/10.1016/j.canlet.2017.05.027 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
lable at ScienceDirect
Cancer Letters 403 (2017) 74e85Contents lists avaiCancer Letters
journal homepage: www.elsevier .com/locate/canletOriginal ArticleThe small molecule inhibitor YK-4-279 disrupts mitotic progression
of neuroblastoma cells, overcomes drug resistance and synergizes
with inhibitors of mitosis
Madhu Kollareddy a, Alice Sherrard b, Ji Hyun Park a, Marianna Szemes a, Kelli Gallacher a,
Zsombor Melegh a, Sebastian Oltean c, Martin Michaelis d, Jindrich Cinatl Jr. e,
Abderrahmane Kaidi b, Karim Malik a, *
a Cancer Epigenetics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
b Nuclear Dynamics Laboratory, School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
c School of Physiology and Pharmacology, University of Bristol, Bristol, UK
d Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK
e Institut für Medizinische Virologie, Klinikum der Goethe-Universit€at, Frankfurt am Main, Germanya r t i c l e i n f o
Article history:
Received 29 March 2017
Received in revised form
24 May 2017
Accepted 26 May 2017
Keywords:
Neuroblastoma
Chemotherapy
YK-4-279
Mitosis
Drug resistance/synergyAbbreviations: ALK, Anaplastic Lymphoma kinase
tor; ERK, extracellular signal-regulated kinases; GFP, g
kilodaltons; MAPK, mitogen-activated protein kina
protein kinase kinase; MTT, 3-(4,5-Dimethylthiazol-2
Bromide; PBS, Phosphate-buffered saline; pHH3, p
RNase A, ribonuclease A; QVD, quinolyl-
diﬂuorophenoxy)- methyl ketone; SDS-PAGE,
polyacrylamide gel electrophoresis; TERT, Telomerase
* Corresponding author. Cancer Epigenetics Labor
Molecular Medicine, Biomedical Sciences Building, U
Bristol, Bristol, BS8 1TD, UK.
E-mail address: K.T.A.Malik@bristol.ac.uk (K. Malik
http://dx.doi.org/10.1016/j.canlet.2017.05.027
0304-3835/© 2017 The Author(s). Published by Elseva b s t r a c t
Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-
risk subset for which new therapeutic agents are urgently required. As well as MYCN ampliﬁcation,
activating point mutations of ALK and NRAS are associated with high-risk and relapsing neuroblastoma.
As both ALK and RAS signal through the MEK/ERK pathway, we sought to evaluate two previously re-
ported inhibitors of ETS-related transcription factors, which are transcriptional mediators of the Ras-
MEK/ERK pathway in other cancers. Here we show that YK-4-279 suppressed growth and triggered
apoptosis in nine neuroblastoma cell lines, while BRD32048, another ETV1 inhibitor, was ineffective.
These results suggest that YK-4-279 acts independently of ETS-related transcription factors. Further
analysis reveals that YK-4-279 induces mitotic arrest in prometaphase, resulting in subsequent cell death.
Mechanistically, we show that YK-4-279 inhibits the formation of kinetochore microtubules, with treated
cells showing a broad range of abnormalities including multipolar, fragmented and unseparated spindles,
together leading to disrupted progression through mitosis. Notably, YK-4-279 does not affect microtu-
bule acetylation, unlike the conventional mitotic poisons paclitaxel and vincristine. Consistent with this,
we demonstrate that YK-4-279 overcomes vincristine-induced resistance in two neuroblastoma cell-line
models. Furthermore, combinations of YK-4-279 with vincristine, paclitaxel or the Aurora kinase A in-
hibitor MLN8237/Alisertib show strong synergy, particularly at low doses. Thus, YK-4-279 could
potentially be used as a single-agent or in combination therapies for the treatment of high-risk and
relapsing neuroblastoma, as well as other cancers.
© 2017 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).; EGF, Epidermal growth fac-
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The clinical heterogeneity of neuroblastoma is reﬂected in the
complex molecular aetiology of this frequently lethal childhood
cancer. Amongst high-risk tumours, which comprise about half of
all neuroblastomas, approximately 40% are dependent on MYCN
gene ampliﬁcation (MNA). Despite extensive genome and tran-
scriptome sequencing analyses, oncogenic mutations in neuro-
blastoma are comparatively rare compared to other cancers [1,2],
although genome-wide analyses have implicated complex dereg-
ulatory events such as enhancer hijacking, leading to Telomerase
reverse transcriptase (TERT) over-expression and ATRX inactivationess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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remain non-MNA high-risk neuroblastomas for which oncogenic
drivers remain unclear, even taking into account activating point
mutations of the Anaplastic Lymphoma Kinase (ALK) gene, which
are apparent in less than 10% of neuroblastomas, encompassing the
non-MNA and MNA high risk subtypes [5]. As a consequence of the
lack of common druggable targets, chemotherapy for neuroblas-
toma still relies largely on DNA damaging agents and inhibitors of
mitosis [6]. We therefore sought to rationalize a broader, but rela-
tively speciﬁc target class for new neuroblastoma therapeutics.
Mutant ALK has been shown to signal through the Mitogen-
activated protein kinase (MAPK) pathway [7], and although only a
low level of RAS-MAPK pathway mutations were reported in neu-
roblastoma diagnosis samples [8], recent sequencing analyses have
shown that RAS pathway mutations are increased in relapsing
neuroblastoma [9,10]. Together ALK and RAS mutations implicate
mitogen/extracellular signal-regulated kinases (MEK1/2) and
extracellular signal-regulated kinases (ERK1/2) in survival and
proliferation of neuroblastoma. Additionally, we recently demon-
strated an unexpected role for the leucine G-protein coupled re-
ceptor (LGR5) as a critical upstream regulator of MEK-ERK signaling
and cell survival of different neuroblastoma genetic subtypes,
including ALK and NRAS mutant lines. Depletion of LGR5 in these
lines led to dramatic attenuation of phosphorylation of MEK1/2 and
ERK1/2 and an increase of BimEL, an apoptosis facilitator down-
stream of ERK, leading to apoptosis [11]. Based on the accumulating
evidence for MAPK pathway involvement in neuroblastoma, we
hypothesized that transcriptional mediators of the Ras-MEK-ERK
pathway, speciﬁcally ETS-related transcription factors [12,13] may
represent a new target class for high-risk neuroblastoma. These
transcription factors, including ETV1, can activate a RAS/ERK-
regulated gene expression program in the absence of ERK activa-
tion [14] and have also been shown to be downstream of ALK
signaling [7,15]. Here we report evaluation of two ETS-family in-
hibitors, BRD32048, an inhibitor of ETV1 [16], and YK-4-279, an
inhibitor of EWS-FLI, ERG and ETV1 [17,18]. We demonstrate that
YK-4-279 triggers apoptosis in a wide variety of neuroblastoma cell
lines at low micromolar concentrations, but does not affect normal
cells. Surprisingly, however, YK-4-279 does not directly affect MEK/
ERK signaling, as might be expected from the ETS-Ras/MAPK as-
sociation, but rather disrupts mitosis. Importantly, we further
demonstrate that YK-4-279 can overcome multidrug resistance,
and also synergize with mitotic inhibitors such as vincristine and
MLN8237, an inhibitor of Aurora kinase A.
Materials and methods
Anticancer compounds and inhibitors
YK-4-279, vincristine, paclitaxel, doxorubicin, etoposide, topotecan, temozolo-
mide, busulfan, cyclophosphamide, trametinib and alisertib (all from Selleckchem),
melphalan (Insight Biotechnology) and cisplatin (Santa Cruz Biotechnology) were
prepared in DMSO and stored at 20 C. Epidermal growth factor and QVD (qui-
nolyl-valyl-O-methylaspartyl-(-2,6-diﬂuorophenoxy)- methyl ketone) were pur-
chased from Sigma.
Cell lines
Neuroblastoma cell lines used for this study were acquired from several re-
sources; Kelly, LAN-1, SK-N-BE(2)-C and IMR32 (Pramila Ramani, Bristol Royal In-
ﬁrmary), SK-N-AS, GIMEN, SH-SY5Y, NF-TERT and NF-730 (Carmel McConville,
ﬁbroblasts from Grant Stewart, University of Birmingham), CHP-212, SHIN, SHEP
(Robert Ross, Fordham University), and RPE-1 h-TERT (ATCC). For resistant lines,
Kelly were obtained from ECACC (Salisbury, UK) and SK-N-AS were from ATCC
(Manassas, VA, USA). The vincristine-resistant sub-lines SK-N-ASrVCR20 [19] and
KellyrVCR10 were established by continuous exposure to increasing drug concen-
trations as previously described [20] and obtained from the Resistant Cancer Cell
Line (RCCL) collection (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html). All neu-
roblastoma cell lines were mycoplasma-free and authenticated using the Promega
PowerPlex 21 system (Euroﬁns, Germany). Most of the cell lines were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM) mixture F12-HAM (Sigma)supplemented with 10% fetal bovine serum (FBS) (Life Technologies), 200 mM L-
Glutamine (Sigma), 100 units/ml penicillin, 0.1 mg/mL streptomycin (Sigma) and 1%
(v/v) non-essential amino acids (Life technologies). GIMEN, LAN1, Kelly, NF-730 and
NF-TERT were cultured in RPMI (Life Technologies).
For imaging studies, lines were transduced with lentivirus constructed by
excising the histone H2B gene from the PGK-H2B-mCherry vector (Addgene), and
inserting it into the PGK-GFP vector (Addgene) to produce GFP-H2B lentivirus.
Lentiviral stocks were produced in HEK 293 cells, using standard protocols. Trans-
ductions were selected for GFP-H2B expressing cells by ﬂow cytometry.
Proliferation and colony formation assays
For MTT assays, 3000e15000 cells were seeded in 80 ml of media. Next day 20 ml
(5 times concentrated) of several drug concentrations prepared in 1:2 serial di-
lutions were added in triplicates. After 72 h, 10 ml of MTT (5 mg/ml) (Sigma) was
added and incubated for 3 h. Thereafter, 50 ml of SDS lysis buffer (10% SDS w/v, 0.01M
HCl, pH 5.5) was added and incubated overnight. MTT absorbance was read using
SpectraMax 190 plate-reader (Molecular Devices) at 570 nm. 650 nm was used as a
reference wavelength. Percentage survival for each dose was calculated by multi-
plying absorbance values by 100 and dividing by control absorbance value. Dose-
response curves were drawn using GraphPad Prism which were used to deter-
mine IC50 values.
For clonogenic assays, 1000 cells were seeded in 6 well plates. After two days
compounds were added. Media and compounds were replenished every four days.
The plates were incubated until several colonies appeared. For colony staining,
media was aspirated followed by PBS wash. Colonies were ﬁxed by buffered neutral
10% formalin (Sigma) for 2 h and washed with PBS three times. Methylene blue (0.3%
(w/v), Sigma) was added to wells and incubated overnight. Plates were thenwashed
several times with water to remove excessive stain and photographed.
Flow cytometry/cell cycle analysis
After drug treatments, medium was collected in 15 ml tubes. Cells were tryp-
sinized and pooled in 15 ml tubes. Cells were centrifuged at 2000 rpm for 5 min at
4 C followed bymedia removal. Cells were washed in PBS once, ﬁxed in 70% ice cold
ethanol and stored at 20 C until analysis. Cells were washed once with PBS,
aspirated and resuspended in 100 ml of RNase A solution (Qiagen 1:1000) and
incubated at 37 C for 15 min. Finally 400 ml of propidium iodide (Sigma: 50 mg/ml)
was added, transferred to ﬂow tubes and incubated at 37 C for 15 min in the dark.
Cells were analyzed using a BD LSRFortessa. Cell cycle data analysis was carried out
using FlowJo software v10.
For combinatorial cell-death and mitosis analysis using Zombie/phospho-
histone H3 (ser10) staining, 2  106 cells were seeded in 10 cm dishes. After dou-
ble thymidine synchronization, YK-4-279 was added and further incubated for 24 h.
The medium was collected and cells detached with Accutase (Millipore). Cells were
pooled with medium and centrifuged (1500 rpm for 5 min). After washing with PBS,
cells were stained with Zombie NIR live-dead stain (BioLegend,1:2500) for 15min in
the dark. Subsequently cells were ﬁxed (0.5% v/v paraformaldehyde, 15 min) and
permeabilized (0.1% Triton X-100 v/v, 15 min). Cells were stained with phospho-
histone H3 (ser10) (1:1000) antibody for 45 min in dark followed by secondary
Alexa 488 antibody for 30 min (Invitrogen). Antibodies were prepared in PBS con-
taining 1% FBS. Finally cells were suspended in Propidium iodide/RNase A as
described in cell cycle analysis. Stained samples were analysed using a BD
LSRFortessa.
Immunoblots, Immunoﬂuorescence and antibodies
Whole cell lysates were prepared using RIPA lysis buffer (25mM Tris-HCl pH 8.0,
150 mM NaCl, 1 mM EDTA, 0.2% SDS, 0.5% NP40 and 0.2% sodium deoxycholate)
supplemented with protease and phosphatase inhibitors (Roche). Cells while in
media were collected in 15 ml tubes, centrifuged at 2000 rpm for 5 min at 4 C,
media aspirated and cells washed with PBS. Lysis buffer was added and samples
were sonicated (Diagenode bioruptor) and clariﬁed at maximum speed at 4 C for
20 min. Protein quantiﬁcation was performed using the Micro BCA kit (Thermo
Fischer Scientiﬁc) and proteins were resolved by SDS-PAGE and transferred to PVDF
membranes (Millipore). Blots were developed using KPL LumiGLO Peroxidase
Chemiluminescent substrate. Antibodies used were phospho-Erk1/2 (4370S,
1:1000), Erk1/2 (9102s, 1:1000), phospho-histone H3 (ser10) (9701, 1:2000), Cyclin
B1 (4138, 1:1000), phosho-Aurora A (T288) (3079, 1:500), Aurora A (3092, 1:500),
Aurora B (3094, 1:500), Acetyl-a-tubulin (Lys40) (5335, 1:1000), a-tubulin (2144S,
1:10000), cleaved caspase-3 (9664, 1; 1000) (all from Cell Signaling Technology),
cleaved PARP (ab32064, 1:3000), Histone H3 (ab10799, 1:3000) (all from Abcam),
p53 (SC-126, 1:1000), p21 (OP64, Oncogene, 1:500) and beta-actin-peroxidase
(A3854, Sigma, 1:40000). Peroxidase conjugated secondary antibodies were pur-
chased from Sigma.
To assess YK-4-279 effects on Ras-MEK/ERK signaling, cells were seeded in
media containing 1% FBS and incubated for 24 h. Cells were subsequently treated
with DMSO or YK-4-279 (SKNAS: 1 mM, GIMEN: 2 mM) or Trametinib (50 nM) for 4 h.
Finally cells were treated with PBS or EGF (200 ng/ml) for further 10 min and whole
cell lysates were prepared for immunoblotting.
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synchronized by double thymidine block. After release from second thymidine
block, cells were treated with DMSO or 2 mM of YK-4-279 for 7 h. Media was aspi-
rated and washed with PBS twice before paraformaldehyde (2% v/v in PBS) ﬁxing for
10min. After washing with PBS, cells were permeabilised using 0.1% Triton X-100 (v/
v) for 10 min. After further washing with PBS, cells were blocked with 1% BSA (w/v)
in PBS for 30 min, and then incubated with antibodies at room temperature for 2 h.
Antibodies used were Aurora A (Cell signaling Technologies, 3092, 1:250), PLK1
(Bethyl Laboratories, A300-252A, 1:500), Eg5 (BioLegend, 627801, 1:250) and a-
tubulin (Thermo Scientiﬁc, 62204, 1:100) After three washes with PBS, labelled
secondary antibodies (Invitrogen 1:1000) were added and incubated in the dark at
room temperature for 45 min. Cells were washed with PBS, DAPI added to cells, and
incubated in the dark for a further 10 min. DAPI was then removed, cells were
washed with PBS, and images acquired using spinning disk confocal microscope
CV1000 (Olympus Life Science).
RNA interference
Transient knockdown was performed using Lipofectamine RNAiMAX (Invi-
trogen). 0.3  106 cells were seeded in 60 mm dishes after reverse transfection
carried out using 50 nM siRNA for 72 h. Opti-MEM media (Invitrogen) was used for
diluting siRNA and RNAiMAX. After 48 h of incubation with siRNA, YK-4-279 was
added and cell lysates were harvested after 24 h for immunoblotting. The siRNA
sequence used for p53 was 50-CAGCAUCUUAUCCGAGUGGAA-3’. A non-targeting
siRNA, 50-UGGUUUACAUGUUUUCUGA-30 was used as a negative control.
Live cell imaging
For real-time proliferation assays, SK-N-AS (5000 cells/well), SK-N-BE(2)-C
(5000 cells/well), Kelly (10,000 cells/well), NF-TERT and NF-730 (3000 cells/well),
and RPE-1 (3000 cells/well) were seeded in 96 well plates in triplicates. After
overnight incubation, different concentrations of YK-4-279 or BRD32048 were
added and immediately incubated in IncuCyte ZOOM live cell imaging system. Phase
conﬂuence was measured every two hours. IncuCyte system scanned and took
images at four different ﬁelds in each well. At the end of the assay raw values were
exported into GraphPad Prism and plotted as percentage phase conﬂuence (repre-
sentative of growth) against time.
For visualization of mitosis, 100,000 cells previously transduced with GFP-H2B
lentivirus were seeded in 35 mm glass bottom Petri dishes. After 24 h incubations
cells were synchronized using the double thymidine block method. After the second
thymidine block, cells were washed with PBS twice and refreshed with medium
without thymidine and immediately added DMSO or YK-4-279 and incubated for
6 h. Images were acquired at 60 magniﬁcation on a wideﬁeld light microscope
(DeltaVision), at 37 C and 5% CO2. GFP was excited using a wavelength of 488 nm,
and tubulin was visualized using SiR-Tubulin (Spirochrome, CY-SC002), at an exci-
tationwavelength of 647 nm, where cells were stained with 1 mMSiR-Tubulin for 1 h
before imaging. Prometaphase cells were identiﬁed based on having compact
chromatin, and lacking a diffuse nuclear GFP signal after the nuclear envelope had
broken down, but without alignment into metaphase. Other phases were identiﬁed
as follows: Metaphase - chromosomes aligned, anaphase - chromosomes segre-
gated, telophase - chromosomes segregated with signs of nuclear envelope reas-
sembly and loss of classic mitotic chromosome appearance. Cells (n > 25) in a
minimum of 15 ﬁelds of view were scored in triplicate treatments by two inde-
pendent assessors. In the case of videos, frameswere taken every threeminutes for a
period of one hour.
Drug combination studies
Drug interactions were analyzed by the method developed by Chou and Talalay.
IC50 values for all compounds used for combination studies were determined prior
to experiment setup. Equipotent ratios of two compounds were prepared across a
wide range of concentrations (sub-lethal to lethal) and the cells treated for 72 h.
Percentage survival values were converted into Fa (fraction affected) values using
the formula, 1-(% survival/100). These values were fed into CompuSyn software to
determine combination index values (<1: synergy, ¼ 1: additive, >1: antagonistic).
Results
Differential efﬁcacy of the ETV1 inhibitors BRD32048 and YK-4-279
on neuroblastoma cell growth
BRD32048 was reported to act as a perturbagen of ETV1 [16]
while YK-4-279 was initially characterized as a disruptor of the
EWS-FLI/DHX9 interaction [17], and later shown to also affect ERG
and ETV1 [18,21]. Our initial screening of these compounds showed
that BRD32048 treatment of SK-N-AS, SK-N-BE(2)-C and Kelly
neuroblastoma cell lines had no effect on cell proliferation (Fig. 1A),
even at highmicromolar concentrations (Supplementary Fig. S1). Incontrast, YK-4-249 reduced cell growth in a dose-dependent
manner at sub-to low-micromolar concentrations (Fig. 1B). YK-4-
279 did not inhibit proliferation of normal human ﬁbroblasts and
epithelial cell lines namely, NF-TERT, NF-730 and RPE-1 (Fig. 1C).
The discrepant effects of these two ETV1 inhibitors suggests that
the primary mode of action of YK-4-279 may, contrary to the
literature and our expectations, be independent of the Ras-MEK/
ERK-ETS(ETV1) axis.
YK-4-279 inhibits neuroblastoma cell growth independent of MEK-
ERK signaling
We next established the IC50's for YK-4-279 in a panel of nine
neuroblastoma cell lines. All these lines were sensitive to YK-4-279
(Fig. 2A), with IC50's ranging from 0.4 to 2 mM. This range is similar
to that reported for Ewing's sarcoma cell lines (0.5e2 mM) [17]. In
order to further explore the selectivity of YK-4-279 action, we
tested YK-4-279(R) and YK-4-279(S) enantiomers [22]. Neuroblas-
toma cell line sensitivity to YK-4-279(S) was approximately two-
fold greater compared to the racemic mix, while neuroblastoma
cell lines were not sensitive to the (R)-enantiomer (IC50: >20 mM)
(Fig. 2AeC and Table 1). With regard to the YK-4-279 sensitivity
proﬁle, no obvious segregation attributable to a particular onco-
genic genotype, such asMYCN ampliﬁcation or mutant NRAS (SK-N-
AS) was apparent (Table 1). This further suggests that sensitivity to
YK-4-279 is not restricted to the Ras-MEK/ERK-ETS axis. In order to
directly evaluate this, we treated SK-N-AS and GIMEN lines with
epidermal growth factor (EGF) to stimulate MEK/ERK signaling, and
assessed whether YK-4-279 could inhibit the increase of phos-
phorylated ERK that accompanies activation of this pathway.
Whilst YK-4-279 was not able to attenuate ERK phosphorylation,
the MEK inhibitor Trametinib totally eliminated ERK phosphory-
lation after EGF treatment (Fig. 2D). Together with our data above,
this experiment demonstrates that the primary mode of action of
YK-4-279 is independent of the Ras-MEK/ERK-ETS axis.
YK-4-279 induces mitotic arrest and apoptosis in neuroblastoma
cells
In order to gain mechanistic insights into the profound effects of
YK-4-279 on neuroblastoma cell proliferation and survival, we
conducted cell cycle analyses. After treatment of SK-N-AS and
GIMEN lines at 0.5 and 1 IC50 values for 24 h, a strong dose -
dependent G2/M arrest was apparent in both neuroblastoma cell-
lines, but not in normal human ﬁbroblasts (NF-730). We also
observed a marked increase in sub-G1 population, indicative of cell
death (Fig. 3A & Fig. S2A). Immunoblotting of corresponding cell
lysates conﬁrmed that YK-4-279 treatment leads to increased PARP
cleavage, detected by the 25 kDa caspase-3 dependent fragment,
thereby conﬁrming apoptosis, aswell as accumulation of phosphoe
histone H3 (serine 10) (pHH3), a marker of chromatin condensation
and earlymitosis (Fig. 3B). YK-4-279 also inducedmitotic arrest and
apoptosis in SK-N-BE(2)-C and CHP-212 cells (Fig. S2B). Caspase-3
dependent apoptosis of SK-N-AS and GIMEN lines was further
conﬁrmed by the detection of 17 and 19 kDa cleaved
caspase-3 fragments and inhibition of apoptosis by QVD treatment
(Fig. S2C). The dramatic induction of pHH3, cleaved PARP and
cleaved caspase-3 was not apparent in NF-730 normal ﬁbroblast
cells (Fig. 3B).
As inhibition of Aurora kinases and polo-like kinases can result
in a similar mitotic phenotype as observed with YK-4-279, their
levels were also assessed by immunoblotting. Neither Aurora A or B
levels were diminished after YK-4-279 treatment, and norwas their
activity, as histone H3 phosphorylation, which depends on Aurora B
[23], is not inhibited. Aurora A kinase activity is also not
Fig. 1. YK-4-279 suppresses neuroblastoma cell growth. Real-time cell growth analysis following BRD32048 treatment using Incucyte Zoom live cell imaging. Phase conﬂuence of
cells is plotted over time. (A) BRD32048 treatment of neuroblastoma lines, (B) YK-4-279 treatment of neuroblastoma lines, (C) Normal human non-cancer cell lines treated with YK-
4-279. Live cell imaging was carried out in 96-well plates in three technical replicates (n ¼ 3; mean ± SD).
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Aurora A (T288) [24] (Fig. 3B). This data clearly indicates that ki-
nase activity of Aurora kinases is not the direct target for YK-4-279,
but rather that they can be considered as markers of the effects of
YK-4-279 on the cell cycle. We also assessed the levels of cyclin B,
which is proteosomally degraded during metaphase [25]. Cyclin B
levels were not affected by YK-4-279 treatment, which, together
with the mitotic kinase evaluation above, suggests that cells were
retained in early mitosis and were not able to proceed into
metaphase.
To gain further mechanistic insight into the mode of action of
YK-4-279, we compared its effects with the classical mitotic in-
hibitors paclitaxel and vincristine, which bind tubulin and/or mi-
crotubules, leading to over-stabilization and destabilization
respectively, and ultimately inhibition of mitosis [26]. Paclitaxel
promotes hyper-polymerization of a-tubulin which can be moni-
tored by increased acetyl-a-tubulin (Lys40) (a marker of tubulin
stabilization) [27]; conversely, de-acetylation is observed in
response to vincristine, which inhibits tubulin polymerization
[28]. YK-4-279 did not increase or decrease acetylation of micro-
tubules signiﬁcantly, thereby ruling out tubulin binding as a
mechanism of action for YK-4-279 (Fig. S2D), and suggesting that
YK-4-279 is targeting a different regulatory step to spindle
poisons.We next investigated whether the apoptosis induced by YK-4-
279 occurs in mitosis or in interphase. After synchronizing cells
by double thymidine block, we treated with YK-4-279 for 24 h and
labelled cells with propidium iodide, pHH3, and Zombie (a live/
dead cell marker). Consistent with our immunoblot analyses, our
ﬂow-cytometry data showed that YK-4-279 induced accumulation
of pHH3 in a dose-dependent manner (Fig. 3C). By plotting pHH3
versus cell death after YK-4-279 treatment, we observed that a
small but signiﬁcant percentage of pHH3 - positive cells stained
positive for the cell death marker (Q2) (Fig. 3D). However, most of
the dead cells are negative for pHH3 (Q1), indicating that only a
small fraction of cells died in mitosis, whereas the majority of cells
died in subsequent interphase. We also found that YK-4-279 could
activate apoptotic checkpoints in a p53-independent manner.
Although YK-4-279 induces high levels of wild-type p53 in GIMEN
cells, together with elevated p21 and cleaved PARP, it induces
apoptosis in both p53 proﬁcient (GIMEN, CHP-212) and deﬁcient
cell lines (SK-N-AS, SK-N-BE(2)-C) (Fig. 3B, Fig. S2B & Table 1). To
conﬁrm this, we knocked down wild-type p53 in GIMEN cells, and
despite the absence of p53, we could still see induction of
apoptosis, with equivalent levels of cell death in both control and
p53 knockdown cells (Fig. S2E). Taken together, our data demon-
strate that YK-4-279 leads to mitotic arrest and can induce p53-
independent apoptosis.
Fig. 2. Enantiomer-speciﬁc YK-4-279 inhibition of neuroblastoma cell lines. (A) Nine neuroblastoma cell lines and two non-cancerous cell lines were further screened by MTT based
cell proliferation assay to determine YK-4-279 sensitivity and IC50 values. (B) Dose-response curves of YK-4-279(S) enantiomer on neuroblastoma cell lines. (C) Activity of the YK-4-
279(R) enantiomer on neuroblastoma cell lines. All MTT assays were carried out in three independent biological replicates each having three technical replicates (n ¼ 3; mean ± SD).
(D) Immunoblotting of SK-N-AS and GIMEN cells to assess effects on EGF-induced MEK/ERK signaling. Cells were treated with YK-4-279 or Trametinib for 4 h, and then PBS or EGF
for a further 10 min before assessing ERK phosphorylation.
Table 1
MTT assay based IC50 (mM) values were determined for nine neuroblastoma cell lines and two normal ﬁbroblasts. Values are means ± SD of three independent experiments.
Cell Line Known genotype YK-4-279: IC50 ± SD YK-4-279(S): IC50 ± SD
IMR32 MNA 0.44 ± 0.03 0.27 ± 0.005
SH-SY5Y ALK mutation 0.81 ± 0.06 0.48 ± 0.03
SK-N-AS NRAS mutation, NF-1 deletion and TP53 truncation 1.30 ± 0.21 0.84 ± 0.08
LAN1 MNA, ALK mutation, TP53 truncation 1.35 ± 0.23 0.78 ± 0.02
SK-N-BE(2)-C MNA, TP53 mutation 1.42 ± 0.11 0.81 ± 0.26
Kelly MNA, ALK mutation, TP53 mutation 1.76 ± 0.09 1.14 ± 0.1
SHIN e 1.98 ± 0.28 1.33 ± 0.32
GIMEN NF-1 deletion 2.00 ± 0.00 1.64 ± 0.26
SHEP 2.93 ± 0.05 1.42 ± 0.05
NF-730 e >20 >20
NF-TERT e >20 >20
MNA: MYCN ampliﬁcation, IC50 (mM): Half maximal inhibitory concentration.
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Our ﬁndings suggest that YK-4-279 treatments interfere with
progression through mitosis. To further evaluate this, we per-
formed live cell imaging to visualize chromatin (with GFP-histone
H2B) and microtubules (with SiR-tubulin, a tubulin-binding ﬂuo-
rogenic probe) [29] in cells treated with YK-4-279 after release
from G1/S-phase synchronization. We observed that while control
cells were at different stages of mitosis, YK-4-279 treated cells were
predominantly in pro-metaphase (Fig. 4A). To probe this further, we
performed time-lapse imaging of single mitotic cells. This
conﬁrmed that while all control cells transitioned from pro-
metaphase to telophase, YK-4-279-treated cells failed to progress
through mitosis and remain largely arrested in prometaphase
(Fig. 4B and Supplementary videos 1e8), consistent with our
immunoblotting of cyclin B and pHH3 (Fig. 3B). This may be
attributable to defects in spindle assembly and/or dynamics, which
is supported by our analyses revealing that cells treated with YK-4-
279 displayed abnormalities in their mitotic spindles, including
unseparated spindle poles (centrosomes), fragmented spindles and
multipolar spindles (Fig. 4C). To gain further insights into themechanisms underlying YK-4-279-induced spindle defects, we
examined the localization of keymitotic kinases. Both Aurora-A and
Polo-like kinase (PLK) orchestrate progression through mitosis by
regulating microtubule spindle assembly. GIMEN cells treated with
YK-4-279 (thus arrested in pro-metaphase) had normal localization
of both Aurora-A (Fig. S3A) and PLK (Fig. S3B) at centrosomes and
kinetochores, respectively. Further, control cells progressed to
metaphase, wherein Aurora-A spreads from centrosomes to mark
polar and kinetochore microtubules (Fig. S3A) and PLK starts
accumulating at the centrosome (Fig. S3B). These observed re-
localizations of Aurora-A and PLK cannot be examined in YK-4-
279 treated GIMEN cells, as they are blocked at pro-metaphase.
Notably, however, YK-4-279 treatment had no discernible effects
on the formation of astral microtubules in pro-metaphase (Fig. S3);
thus, raising the possibility that YK-4-279 may hinder the forma-
tion of polar and/or kinetochore microtubules that are required for
transition from pro-metaphase to metaphase. Given that Eg5
kinesin is a key regulator of this process, we hypothesized that
YK-4-279 may interfere with its function, and found that in DMSO-
treated pro-metaphase cells Eg5 accumulates on the spindle, while
YK-4-279 treatment appears to interfere with Eg5 distribution
Fig. 3. YK-4-279 induces mitotic arrest and apoptosis in neuroblastoma cell lines. (A) Propidium-iodide based cell cycle analysis of YK-4-279 treated cells using ﬂow cytometry. Cells
were treated for 24 hwith 0.5 and1xIC50 concentrations. Cell cycle analysiswas carriedout in three independent biological replicates. (B) SK-N-AS, GIMENandNF-730were treatedwith
DMSO (D) or two doses of YK-4-279 for 24 h and protein lysates harvested. Blotswere probed for several cell cycle and cell deathmarkers. All neuroblastoma cell lines showed increase of
phospho-histoneH3 (Ser10(pHH3), cleaved PARPand active caspase-3. Actinwasused as a loading control. (C) Flowcytometrywith triple staining forphospho-histoneH3 (Ser10) (mitotic
cells). Dot plot showing DNA content (X-axis) against phospho-histone H3 (Y-axis). Quantiﬁcation bar graphs of percentage mitotic cells (right side). Data shown as mean ± SD of three
technical replicates. (D) Zombie live/dead cell marker versus phospho-histone H3(Ser10). Cells synchronized using double-thymidine block were treated with YK-4-279 for 24 h
after release. Cells were stained with Zombie dye followed by phospho-histone H3 (Ser10) after ﬁxation and permeabilization and subsequently with propidium iodide. Dot plots of
phospho-histone H3 positive cells against dead cells. Q1 and Q2 represent percentage dead cells (Q1 and Q2) negative or positive for phospho-histone H3, respectively. Data shown as
mean ± SD of three technical replicates. **P < 0.01, ***P < 0.001. Unpaired Student t-test was used to assess the signiﬁcance of difference between the control and treated samples.
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anistic insights into how YK-4-279 interferes with spindle assem-
bly/dynamics and mitotic progression, eventually inducing
neuroblastoma cell death.
Supplementary videos related to this article can be found at
http://dx.doi.org/10.1016/j.canlet.2017.05.027YK-4-279 overcomes vincristine resistance and multidrug resistance
Vincristine is one of the most effective chemotherapeutic agents
for neuroblastoma [30]. However neuroblastoma patients and cell
lines acquire resistance to vincristine [31]. Given the probability
that YK-4-279 acts through a mechanism other than microtubule
Fig. 4. Disruption of mitosis induced by YK-4-279. (A) Four neuroblastoma cell lines, SK-N-AS, GIMEN, SK-N-BE(2)-C and SH-SY5Y were treated DMSO or with 1 mM YK-4-279 (5 mM
was used for GIMEN). Prior to treatment cells were synchronized by standard double thymidine block protocol. Immediately after release, cells were treated with YK-4-279 for six
hours. The graph shows the percentage of cells at distinct phases of mitosis, which were scored based on chromatin organization, in three independent replicates (n > 25). (B) SK-N-
AS, GIMEN, SK-N-BE(2)-C and SH-SY5Y representative mitotic structures (Red: microtubules, Green: chromosomes) from three independent replicates. Diverse microtubule or-
ganization is evident from the images. All DMSO treated cells showed typical metaphase equatorial plates and progressed through mitosis and segregated chromosomes within the
nine-minute time frame, whereas YK-4-279 cells were mostly stuck at prometaphase. (C) Static images of four live neuroblastoma cell lines. The range of abnormalities include
fragmented (SK-N-AS), unseparated (GIMEN) and multipolar spindles (SK-N-BE(2)-C and SH-SY5Y) (Red: microtubules, Green: chromosomes). Images shownwere representative of
three independent replicates (n > 25). See also videos in Supplementary information. (D) Confocal microscopy showing immunoﬂuorescent localization of Eg5 (pink) in YK-4-279-
treated GIMEN cells. Chromatin is stained with DAPI (blue).
M. Kollareddy et al. / Cancer Letters 403 (2017) 74e8580polymerization, we assessed the potential of YK-4-279 in over-
coming vincristine induced resistance in neuroblastoma cell line
models. We tested YK-4-279 on SK-N-AS and Kelly cell lines with
acquired vincristine e resistance, named SK-N-ASrVCR20 and Kel-
lyrVCR10 respectively. Vincristine treatment did not result in typical
sigmoidal-dose response even at the highest concentration tested
on SK-N-ASrVCR20 cells (>7-fold resistant relative to the parental
line) (Fig. 5A). Similarly, KellyrVCR10 is 30-fold resistant to
vincristine (Fig. 5B). These cell lines are also more resistant to
paclitaxel (SK-N-AS ¼ 14-fold; Kelly ¼ 50-fold) than vincristine in
terms of IC50 values. Strikingly both VCR resistant cell lines are as
sensitive as their parental counterparts to YK-4-279 (Fig. 5A and B).
We further tested several drugs (topotecan, doxorubicin, etoposide,
cisplatin, melphalan, busulphan and temozolomide) that are
routinely used as front-line therapy in neuroblastoma to evaluate
multidrug-resistance phenotype. SK-N-ASrVCR20 is cross-resistant
to almost all drugs we tested (6e19 fold), except cisplatin (1.5
fold) and temozolomide (1.04-fold) (Table 2). Similarly, KellyrVCR10
is also cross-resistant to doxorubicin (3-fold), etoposide (3-fold),
busulfan (1.7-fold), but not to temozolomide (1.2-fold) and almost
equally sensitive to cisplatin, melphalan and topotecan as their
parental counterparts. We did not see any inhibition of prolifera-
tion with Cyclophosphamide even at millimolar concentrations.
This analysis demonstrates that only YK-4-279 and temozolomide
can overcome VCR resistance in both SK-N-ASrVCR20 and
KellyrVCR10 cell lines, unlike many other currently used chemo-
therapeutic drugs.
We also performed clonogenic assay to assess the ability of YK-
4-279 to overcome resistance. In line with cell proliferation data,
YK-4-279 (even at very low concentration) reduced the colony
formation in both sensitive and resistant SK-N-AS cell linesequivalently, whereas SK-N-ASrVCR20 is highly resistant and cross-
resistant to vincristine and paclitaxel respectively (Fig. 5C). In order
to conﬁrm that these effects of YK-4-279 were attributable to
disruption of mitosis as observed in our cell-line panel, we treated
parental and resistant cell lines with vincristine or paclitaxel or YK-
4-279 at 2  IC50 for immunoblotting. As expected vincristine,
paclitaxel and YK-4-279 induced phosphorylation of Histone H3
and cleaved PARP in parental cell lines (Fig. 5D). However resistant
counterparts did not undergo either mitotic arrest or apoptosis
when treated with vincristine or paclitaxel. In contrast YK-4-279
induced mitotic arrest and apoptosis in resistant cell lines
(Fig. 5D). This further supports that YK-4-279 has a novel mecha-
nism for disrupting mitosis distinct to vincristine or paclitaxel.
Together, our data shows that YK-4-279 overcomes vincristine
resistance and its activity is not restricted by multidrug-resistance.
YK-4-279 synergizes with vincristine, paclitaxel and Alisertib
Our cell cycle, cell death and live-cell imaging data show that
YK-4-279 is inducing mitotic perturbations by mechanism(s) that
are independent of Aurora kinase A, and different from paclitaxel
and vincristine. We therefore explored whether YK-4-29 can
further enhance the sensitivity to mitotic inhibitors. We deter-
mined IC50 values for vincristine, paclitaxel and Alisertib/MLN8237,
an Aurora kinase A inhibitor in clinical trials for neuroblastoma
[24,32] and then combined the drugs in six combinational equi-
potent ratios based on the IC50 values in order to assess effects on
proliferation and obtain combination indices (CI) by the method of
Chou and Talaly [33]. Almost all combination dose-response curves
shifted towards sensitive side of the graph indicating that combi-
nations were more efﬁcient in inhibiting cell proliferation. Out of
Fig. 5. YK-4-279 circumvents resistance to vincristine. (A) Proliferation assays show that SK-N-ASrVCR20 are resistant to vincristine and paclitaxel, but not YK-4-279. (B) as above for
Kelly rVCR10 cells. Vincristine resistant cell lines and their parental counterparts assessed after 72 h of YK-4-279 treatment by MTT assay. Dose-response curves shown are
representative of three independent replicates. (C) SK-N-AS and SK-N-ASrVCR20 lines were seeded in 6 well plates and treated with vincristine, paclitaxel and YK-4-279 with regular
replenishments. After 18 days, cells were stained with methylene blue and imaged. (D) SK-N-ASrVCR20 and KellyrVCR10 lysates were prepared 24 h after treatment with 2 IC50
concentrations of vincristine, paclitaxel and YK-4-279. Blots were probed for mitotic and apoptotic markers, demonstrating unimpaired efﬁcacy of YK-4-279.
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GIMEN, three resulted in synergy with CI values 0.37, 0.4 and 0.57
(Fig. 6A). In SK-N-AS an even stronger synergy was observed (CI
values: 0.18, 0.3, 0.36 and 0.73) (Fig. 6B). Only two synergistic
combinations were observed in SK-N-BE(2)-C (Fig. S5). With
respect to paclitaxel, three combinations resulted in synergy in
GIMEN cells (CI: 0.44, 0.47, 0.77), and one close to additive effect
(0.9) (Fig. 6C). Similarly, synergy was attained in SK-N-AS, with
three CI values of approximately 0.5 (Fig. 6D), and in SK-N-BE(2)-C
cells, particularly at lower doses (CI: 0.6, 0.64, 0.68, 0.8) (Fig. S5).
Finally we also tested YK-4-279 in combination with Alisertib/
MLN8237. In GIMEN cells, ﬁve out of six combinations were
strongly synergistic (CI range: 0.27e0.53) (Fig. 6E), whereas SK-N-
BE(2)-C cells showed four combinations with signiﬁcant synergy(CI: 0.6e0.8) (Fig. 6F). In contrast, SK-N-AS cells exhibited only two
combinations with synergy (CI: 0.6 and 0.7) (Fig. S5). Together
these experiments highlight the potential for YK-4-279 as an
adjuvant chemotherapeutic agent, enabling use of lower doses of
inhibitors of mitosis in current clinical use.
Discussion
In this study, we have shown that the small molecule inhibitor
YK-4-279 causes apoptosis of neuroblastoma cell lines, irrespective
of their diverse oncogenic genotypes. This inhibitor dramatically
disrupts progression through mitosis by a mechanism different
from the commonly used spindle poisons paclitaxel and vincristine,
and is thereby able to (a) overcome cancer cell resistance to
Table 2
Resistance and cross-resistance proﬁles of SK-N-ASrVCR20 and KellyrVCR10 resistant
cell lines. IC50 values are means ± SD of three independent experiments. Values in
parentheses represent resistance factor values indicative of fold-resistance. IC50
(mM) values of parent versus resistant cell lines were used to determine resistance
factor values.
Compound SK-N-AS SK-N-ASrVCR20
YK-4-279 1.3000 ± 0.0900 1.080 ± 0.100 (0.8)
Vincristine 0.0015 ± 0.2300 >0.01 ± 0.000 (>7)
Paclitaxel 0.0050 ± 0.2900 0.072 ± 0.007 (14)
Topotecan 0.0053 ± 0.0002 0.100 ± 0.000 (19)
Doxorubicin 0.0600 ± 0.0005 >1.00 ± 0.000 (>17)
Melphalan 2.3600 ± 0.0700 43.20 ± 1.272 (18)
Etoposide 0.5300 ± 0.0800 3.750 ± 0.750 (7)
Busulfan 122.00 ± 4.9497 768.0 ± 55.86 (6)
Cisplatin 174.00 ± 11.718 261.0 ± 31.81 (1.5)
Temozolomide 486.50 ± 70.000 510.0 ± 51.61 (1.04)
Compound Kelly KellyrVCR10
YK-4-279 1.5900 ± 0.1600 1.470 ± 0.060 (0.9)
Vincristine 0.0010 ± 0.0000 0.030 ± 0.003 (30)
Paclitaxel 0.0010 ± 0.0000 0.050 ± 0.007 (50)
Doxorubicin 0.0365 ± 0.0007 0.126 ± 0.012 (3.45)
Etoposide 0.3800 ± 0.0332 1.190 ± 0.084 (3.13)
Busulfan 85.000 ± 7.4246 146.0 ± 39.59 (1.72)
Temozolomide 195.00 ± 14.142 231.5 ± 13.43 (1.2)
Cisplatin 81.000 ± 10.465 93.00 ± 15.90 (1.15)
Melphalan 1.7200 ± 0.0282 1.910 ± 0.028 (1.11)
Topotecan 0.0062 ± 0.0000 0.006 ± 0.000 (0.96)
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279 and structurally related compounds may be highly effective
for neuroblastoma therapy, either as a single agent or in combi-
nation with other drugs targeting mitosis.
Although originally reported as an agent that selectively dis-
rupts the EWS-FLI/DHX9 interaction in Ewing's sarcoma [17], our
study suggests that YK-4-279 is capable of targeting a much wider
variety of cancers. Examination of YK-4-279 data available on the
“Genomics of drug sensitivity of cancer” database (GDSC: http://
www.cancerrxgene.org) reveals that the majority of the 821 can-
cer cell lines screened against YK-4-279 were sensitive, with IC50's
as low as 420 nM, ranging to as high as 798 mM. These data do not
highlight a clear genotype underlying YK-4-279 sensitivity. Neu-
roblastomas do not possess the EWS-FLI fusion protein, and pep-
tides disrupting the EWS-FLI/DHX9 interactionwere reported to be
ineffective against SK-N-AS cells [17]. We did not observe any
changes in the levels of DHX9 following YK-4-279 treatment, or any
effects on cell proliferation following DHX9 knockdown (data not
shown). All neuroblastoma cell lines screened were sensitive to YK-
4-279 within a narrow range of IC50's, but normal ﬁbroblasts and
epithelial cells were not as sensitive to YK-4-279, consistent with
the target and/or pathway(s) being more common, but neverthe-
less cancer-cell speciﬁc. Our demonstration that YK-4-279 sensi-
tivity is enantiomer-speciﬁc highlights the potential of YK-4-279 as
a selective therapeutic agent, despite the precise target(s)
remaining unknown.
We speculate that YK-4-279 is able to disrupt key protein in-
teractions required for controlled mitosis and proliferation of can-
cers cells. Ourmechanistic experiments demonstrate that YK-4-279
clearly exerts its anti-cancer effects via disruption of mitosis. The
mitotic defects induced by YK-4-279 lead to cells developing
multipolar and fragmented spindles, as well as unseparated spindle
poles, and being unable to transition from prometaphase to
metaphase. Our data did not reveal obvious differential expression
of mitotic regulatory proteins, or indeed the disruption of early
kinase signaling events, such as Aurora A auto-phosphorylation or
histone 3 phosphorylation. Entry into, and progression through,
mitosis involves exquisitely sensitive and coordinatedspatiotemporal signaling involving multiple protein complexes
[34], and YK-4-279 may provide an excellent tool compound for
future dissection of subtle mitotic phenotypes corresponding with
particular proteins using the Mitocheck database (http://www.
mitocheck.org/) [35]. Our microscopy studies also suggested that
YK-4-279 was not interfering with tubulin and microtubule as-
sembly, as wewere clearly able to monitor tubulinwith SiR-tubulin
after YK-4-279 treatment, in contrast to vincristine and paclitaxel-
treated cells, where SiR-tubulin binding was minimal, presumably
due to competitive binding as SiR-tubulin is based on docetaxel
[29]. This difference between the drugs was also apparent when
assessing acetylated tubulin, which was unaffected by YK-4-279.
Importantly, we have demonstrated that this difference can be
therapeutically exploited to overcome resistance to vincristine.
Although vincristine is used for relapsing and refractory neuro-
blastoma therapy [36], resistance is apparent [31,37] together with
cross-resistance [38,39]. We have shown that vincristine-resistant
cell lines can be driven to mitotic arrest and apoptosis by YK-4-
279, and also demonstrated that resistant lines which exhibit
cross-resistance to several other drugs commonly used as neuro-
blastoma chemotherapeutics, including topotecan, doxorubicin,
etoposide, cisplatin, melphalan, and busulphan, remain susceptible
to YK-4-279. This underlines the possible advantages of YK-4-279
as a therapeutic agent for neuroblastoma. Interestingly, our
studies also show that temozolomide, which is included in BEACON
clinical trial, was the only other agent which was not susceptible to
cross-resistance in our two models, thus providing a rationale for
temozolomide plus vincristine combination therapies. Combina-
tions with YK-4-279 may also be effective when the in vivo/clinical
efﬁcacy of YK-4-279 is veriﬁed. As well as countering resistance to
spindle poisons, we further established that YK-4-279 synergized
with vincristine, paclitaxel and Alisertib, especially at lower doses.
These combinations may therefore achieve maximal therapeutic
responses with minimal side-effects; despite its widespread usage
in chemotherapy, vincristine is known to have considerable toxic
side-effects [40], and our study suggests that YK-4-279 may
improve the chemotherapy standard of care.
Our triple staining ﬂow cytometry data show that most of the
cell death caused by YK-4-279 is probably happening in interphase
rather than there being extensive death in mitosis. Thus our data
suggest that spindle assembly checkpoint [41] although induced,
may permit slippage into interphase over time. Interestingly, neu-
roblastoma cell lines have been shown to be sensitive to depletion
of Centrosome-associated protein E (CENPE), a prometaphase
protein required for establishment and maintenance of kineto-
chores and spindle microtubule connections [42]. Unlike YK-4-279,
CENPE depletion was selective for MYCN-ampliﬁed lines, suggest-
ing that the target for YK-4-279 is not simply disrupting kineto-
chore function. However, the CENPE inhibitor GSK923295 was
effective against a broad spectrum of neuroblastoma cell lines.
Together with our study, this suggests that a systematic search for
earlymitotic vulnerabilities in neuroblastoma should be considered
in the future.
Cell fate upon treatment with mitotic inhibitors depends upon
the type and concentration of drug used - cells may produce
aneuploid progeny or undergo mitotic slippage or undergo cell
death in mitosis or interphase [43]. However, we did not see any
polyploid populations in any of the cell-lines analyzed, although
our analyses of GIMEN cells suggest that mitotic defects induced by
YK-4-279 did activate the G1 checkpoint, as evidenced by the
upregulation of functional p53 and its transcriptional target p21.
Knockdown of p53 in GIMEN cells did not alleviate cell death,
however, and both SK-N-AS and SK-N-BE(2)-C cells have TP53
mutations, suggesting that apoptosis is instigated by p53-
independent mechanisms. These could involve p73, which has
Fig. 6. YK-4-279 synergizes with mitotic inhibitors. (A) GIMEN cells line were treated either singly, or with combinations of YK-4-279 and vincristine, and the MTT proliferation
assay was carried out after 72 h. Dose-response curves are shown in the upper panels and Combination Index (CI) plots in the lower panels. Percentage survival values were
transformed into Fraction affected (Fa) values and used to calculate combination index (measure of synergy, additivity and antagonism) using CompuSyn software. (B) Combination
studies for SK-N-AS (YK-4-279 with Vincristine), (C) GIMEN (YK-4-279 with paclitaxel), (D) SK-N-AS (YK-4-279 with paclitaxel), (E) GIMEN (YK-4-279 with Alisertib) and (F) SK-N-
BE(2)-C (YK-4-279 with Alisertib).
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induce apoptosis [44], or MYC family proteins, which are highly
expressed in neuroblastoma [45]. c-MYC was recently shown to be
a key regulator of apoptosis ensuing from mitotic defects, sensi-
tizing cancer cells to inhibitors of mitosis by transcriptional upre-
gulation of pro-apoptotic BH3-only proteins as well as suppression
of pro-survival Bcl-xL [46].In summary, our study demonstrates that YK-4-279 is a
powerful inhibitor of mitosis able to elicit apoptosis in a variety of
neuroblastoma cell lines with different oncogenic drivers. It is also
capable of countering drug resistance, and synergizing with in-
hibitors of mitosis. We are currently continuing efforts to deﬁne the
target(s) of YK-4-279 and the mechanism by which apoptosis is
induced. Compounds of this class likely represent an important
M. Kollareddy et al. / Cancer Letters 403 (2017) 74e8584addition to the current chemotherapy options for neuroblastoma,
as well as for other cancers.
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